Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA3 | P42263 | 1/20 | 0.65 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 6/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5759402 | 0.84 | GRIA3 (0.72) | GRIA3GRIA4HPGDTAS1R3TAS1R1 | |
| SCHEMBL5791567 | 0.84 | GRIA3 (0.72) | GRIA3GRIA4HPGDTAS1R3TAS1R1 | |
| SCHEMBL5758784 | 0.83 | GRIA3 (0.70) | GRIA3GRIA4HPGDTAS1R3TAS1R1 | |
| SCHEMBL5758316 | 0.81 | GRIA3 (0.97) | GRIA3GRIA4HPGDALDH1A1HTT | |
| SCHEMBL5758530 | 0.80 | GRIA3 (0.65) | GRIA3GRIA4HPGDLRRK2TAS1R3 | |
| SCHEMBL5760125 | 0.79 | GRIA3 (1.00) | GRIA3GRIA4HPGDALDH1A1TSHR | |
| Farampator SCHEMBL677135 | 0.79 | GRIA3 (1.00) | GRIA3GRIA4HPGDALDH1A1TSHR | |
| Cx-717 SCHEMBL243542 | 0.78 | GRIA3 (0.76) | GRIA3GRIA4HPGDALDH1A1HTT | |
| SCHEMBL5756335 | 0.78 | GRIA3 (0.62) | GRIA3GRIA4HPGDTAS1R3TAS1R1 | |
| SCHEMBL5757878 | 0.77 | GRIA3 (0.74) | GRIA3GRIA4HPGDTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276462-A1 | Method of treating cognitive decline due to sleep deprivation and stress | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2006-12-07 | — | — | US | claimed |
| EP-1592464-A2 | METHOD OF TREATING COGNITIVE DECLINE DUE TO SLEEP DEPRIVATION AND STRESS | CORTEX PHARMACEUTICALS, INC. (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004062616-A2 | METHOD OF TREATING COGNITIVE DECLINE DUE TO SLEEP DEPRIVATION AND STRESS | CORTEX PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| EP-0960105-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | The Regents of the University of California (US) | 1999-12-01 | — | — | EP | claimed |
| WO-1998035950-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | claimed |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | disclosed |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2010-02-11 | — | — | US | disclosed |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2010-02-11 | — | — | US | disclosed |
| US-20060276462-A1 | Method of treating cognitive decline due to sleep deprivation and stress | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2006-12-07 | — | — | US | disclosed |
| EP-1428534-B1 | BENZOFURAZAN DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | UNIV CALIFORNIA (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1592464-A2 | METHOD OF TREATING COGNITIVE DECLINE DUE TO SLEEP DEPRIVATION AND STRESS | CORTEX PHARMACEUTICALS, INC. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004062616-A2 | METHOD OF TREATING COGNITIVE DECLINE DUE TO SLEEP DEPRIVATION AND STRESS | CORTEX PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-1428534-A1 | BENZOFURAZAN DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | The Regents of the University of California (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-0960105-B1 | BENZOFURAZAN COMPOUNDS THAT ENHANCE AMPA RECEPTOR ACTIVITY | UNIV CALIFORNIA (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6730677-B2 | TREATING MEMORY IMPAIRMENT; ENHANCE EXCITATORY SYNAPTIC ACTIVITY IN ORDER TO RESTORE AN IMBALANCE BETWEEN BRAIN SUBREGIONS, AS IN TREATMENT OF SCHIZOPHRENIA OR SCHIZOPHRENIFORM BEHAVIOR. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-05-04 | — | — | US | disclosed |
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | CORTEX PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | disclosed |
| US-6313115-B1 | ALLEVIATE IMPAIRMENT OF MEMORY, OR OTHER COGNITIVE FUNCTIONS CAUSED BY HYPOGLUTAMATERGIC CONDITION OR BY DEFICIENCY IN NUMBER OR STRENGTH OF EXCITATORY SYNAPSES OR IN NUMBER OF AMPA RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-11-06 | — | — | US | disclosed |
| EP-0960105-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | The Regents of the University of California (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998035950-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | GRIN1, GABRE, GRM1 | GRIA3 11/4885GRIA4 4/4885HPGD 1707/4885 |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, BDNF, NGF | GRIA3 72/4885GRIA4 64/4885HPGD 3434/4885 |
| US-20060276462-A1 | Method of treating cognitive decline due to sleep deprivation and stress | GRIN2A, GRIN1, GRIK5 | GRIA3 30/4885GRIA4 21/4885HPGD 704/4885 |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, NGF, BDNF | GRIA3 231/4885GRIA4 140/4885HPGD 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.